Skip to main content
. 2008 Oct 6;52(12):4356–4369. doi: 10.1128/AAC.00444-08

FIG. 2.

FIG. 2.

PSI-6130 exhibits potent activity against GT-1b and GT-1a NS5B clinical isolates. The inhibitory activity of PSI-6130 was evaluated using a panel of transient replicons containing the NS5B coding region derived from clinical isolates of treatment-naïve HCV GT-1a- or GT-1b-infected patients. After the amplified NS5B region was cloned from a patient serum into the corresponding genotype transient shuttle replicon, 96 individual molecular clones were pooled for each clinical isolate to mimic the natural polymorphism in the patient. The activity of PSI-6130 was assessed using the HCV transient replicon assay.